

Index

A

- ABO blood-group system, 4, 118
- Admixture-based analysis, human diversity, 17–26
- Africa
 - ancestry of African Americans in New York City, 114–115
 - blood pressure studies, 112–114
 - Darwinian selection and genetic variation
 - chronic kidney disease, 64–68
 - lactase persistence, 63–64
 - malaria, 64
 - overview, 62–63
 - genetic and phenotypic variation among humans, 55
 - genetic diversity patterns, 56–59
 - linguistic, cultural, and subsistence diversity, 56–57
 - population purity in human genomic research, 37
 - prospects for study, 68
 - uniparental marker analysis, 59–62
- Ancestry, testing as typological thinking, 17–19
- APOL1*, 66–67, 114
- Aryan, 98–99, 102
- Ashkenazi Jew, 121
- Ati-Sudra, 35

B

- Bactro–Margiana Archaeological Complex (BMAC), 98
- Blair, Tony, 30
- Blood pressure. *See* Hypertension
- BMAC. *See* Bactro–Margiana Archaeological Complex
- Brahmin, 34–35, 98–100, 102

C

- Caesar, 41
- Caste. *See* Social diversity
- CCR5*, 49
- CEPH-HGDP, 58
- Chronic kidney disease (CKD), Darwinian selection and genetic variation in Africa, 64–68
- CKD. *See* Chronic kidney disease
- Clinton, Bill, 30
- Copy number variant, 125
- Cystic fibrosis, race differences, 122

D

- Darwin, Charles, 3, 16–17, 20–21, 26–27
- Diabetes type 2, Native American susceptibility, 92–93
- DISTRUCT program, 27
- Dravidian, 99–100

E

- Epilepsy Phenome/Genome Project, 126
- Epstein, Steven, 30
- Europe
 - agriculture history, 43
 - ancient DNA studies, 48–49
 - Darwinian selection, 49–50
 - demographic factors shaping genetic diversity, 42–45
 - genome-wide data, 45–47
 - migration events, 42–44
 - overview of genetic studies, 41–42
 - prospects for study, 50–51
 - uniparental marker analysis, 47–48, 51

F

- Fixation index, 83
- Focal segmental glomerulosclerosis. *See* Chronic kidney disease
- ForSim program, 24
- Founder effect, 36
- FOXRED2*, 66

G

- G6PD*, 64
- Genetic ancestry, overview, 44
- Genome-wide association study (GWAS), 31, 36, 112, 119–120, 123–124
- GWAS. *See* Genome-wide association study

H

- Haldane, J.B.S., 10, 64
- HapMap Project, 58, 120
- HbS, 64, 121
- HCV. *See* Hepatitis C virus
- Hepatitis C virus (HCV), 122–125
- Herodotus, 41

Index

HIV. *See* Human immunodeficiency virus

Homo erectus, 8

Hooton, E.A., 20

HUGO Pan-Asian Consortium, 31, 84

Human Genome Project, 30–31, 118, 126

Human immunodeficiency virus (HIV), resistance, 49

Hypertension, race differences, 33–34, 110–112

I

IL28B, 122–125

India

caste genotyping, 34–35, 97–105

contemporary social structure, 81–82

earliest settlers, 82

large sets of genomic markers, 84–85

migrations, 79–81

uniparental marker analysis of population diversity
and structure, 82–84

Indian Genome Project, 35, 38

IPASS. *See* Iressa Pan-Asian study

Iressa Pan-Asian study (IPASS), 31

K

Kimura, Motoo, 11, 119

Kshatriya, 34, 103

L

Lactase persistence (LP), Darwinian selection and
genetic variation in Africa, 63–64

Last glacial maximum (LGM), 42, 47, 88–89

Latin American

ancestry of Hispanics in New York City, 114–115

initial settlement, 88–89

migrations, 88–90

phylogenetic tree, 91

self-perceived ancestry, 94

LCT, 50

Lennox–Gastaut syndrome, 125

Lewontin, Richard, 119

LGM. *See* Last glacial maximum

Linnaeus, Carl, 16, 20, 27

LP. *See* Lactase persistence

M

Malaria, Darwinian selection and genetic variation
in Africa, 64, 112, 121

Malinche, 90, 92

Mendel, Gregor, 3–4, 120

Missing heritability problem, 5

Mitochondrial DNA (mtDNA)

accumulated changes, 79

African genetic diversity analysis, 59–62

ancient DNA studies, 48–49

European genetic diversity analysis, 48, 51

India population diversity and structure studies,
82–84

Latin American/Native American studies, 87–88,
90, 92

mtDNA. *See* Mitochondrial DNA

Mueller, Max, 99

MYH9, 66

N

Native American

diabetes susceptibility, 92–93

initial settlement, 88–89

migrations, 88–90

phylogenetic tree, 91

population purity in human genomic research,
36–37

Neanderthal, 43–44

Nonrecombining portion of the Y chromosome
(NRY)

accumulated changes, 79

African genetic diversity analysis, 59–62

European genetic diversity analysis, 48, 51

India population diversity and structure studies,
82–84

Latin American/Native American studies, 87–88,
90, 92

NRY. *See* Nonrecombining portion of the Y
chromosome

O

1000 Genomes Project, The, 58

P

Pager, Devah, 35

Patents, biotechnology, 38

PCA. *See* Principal component analysis

Personalized medicine

common variation influencing disease risk and drug
response, 122–125

drug discovery and clinical use implications,
125–126

genetic diversity overview, 118–120

geographic variation for common variation versus
variants influencing disease risk and drug
response, 120

hepatitis C virus treatment, 122–125

population specificity of Mendelian mutations,
120–121

race-based medicine, 11–13, 34

Plasmodium. *See* Malaria

POPRES study, 45, 47

- Population
definition, 18–19, 31–34
purity in human genomic research, 36–37
subpopulation emergence, 78
- Principal component analysis (PCA), European genetic diversity, 46
- Prostate cancer, race differences, 33
- R**
- Race
biological and biomedical research impact, 108–110
definition, 6–8, 15–17
genetics, 3–4
history of study, 20–24
migrations, 3
origins, 8–11
overview, 1–3
personalized medicine, 11–13, 34
prospects for genetic diversity studies, 11
variation in traits and diseases, 4–5, 33–34, 110–112
- S**
- Sampling, human genetic diversity, 37–38
- Single-nucleotide polymorphism (SNP), 19, 23, 25, 31–32, 35, 37, 119, 122
- SLC45A2*, 49
- SNP. *See* Single-nucleotide polymorphism
- Social diversity
caste genotyping in India, 34–35, 97–105
- population purity in human genomic research, 36–37
- sampling for human genetic diversity, 37–38
- socioeconomic variation effects, 38
- Species origin, historical perspective, 16
- STRUCTURE program, 22, 32
- Sudra, 34, 103
- Syngenta, 33
- T**
- Tay–Sachs disease, 121
- The most recent common ancestor (TMRCA), Africa, 59–60, 64
- Thrifty genotype hypothesis, 93
- TLR6*, 49
- TMRCA. *See* The most recent common ancestor
- Trypanosoma brucei*, 67
- V**
- Vaisya, 34
- Venter, J. Craig, 31
- W**
- Wallace, Alfred, 16
- Watson, James D., 31
- Y**
- Y chromosome. *See* Nonrecombining portion of the Y chromosome